查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133474

全球術後疼痛治療市場 - 2022-2029

Global Post-operative Pain Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

術後疼痛治療藥物市場的增長是由手術數量的增加、市場上新藥的推出和研發活動、新興國家老年人口的增加、患病率的增加所推動的急性疾病的增加，以及參與手術和手術的患者數量的增加。

手術數量的增加有望推動市場增長

癌症和眼科等各種手術數量的增加預計將在預測期內提振市場。根據美國整形外科醫師協會 2020 年數據報告，2020 年將進行約 1560 萬例整容手術，其中 230 萬例為整容手術，1320 萬例為微創整容手術。此外，女性接受整容手術的次數比男性多，2020年，女性約佔所有整容手術的92%，男性約佔所有整容手術的8%。此外，在 13-19 歲的兒童中，只有 2% 的兒童參與了手術。常見的青少年手術包括眼瞼手術、鼻整形術、耳部手術、激光脫毛和激光換膚。一位醫療保健提供者推薦使用非甾體抗炎藥來幫助減輕整容手術後的疼痛。

此外，根據發表在《南非生理學雜誌》上的一篇論文，骨關節炎在 40 歲時的發病/進展率估計為 22%。如果疾病更嚴重且有限的管理不能有效緩解疼痛，醫療專業人員建議進行關節置換手術。隨著手術數量的增加，全球對術後藥物的需求也在增加。

術後疼痛治療藥物的副作用阻礙市場增長

但是，所有藥物都有副作用，例如，所有阿片類藥物都有限制其使用的副作用。與阿片類藥物使用相關的主要副作用是呼吸抑制。與藥物過量和術後止痛藥相關的副作用案例不斷增加，限制了整個市場的增長。

COVID-19 影響分析

COVID-19 的出現對全球術後止痛藥市場產生了重大影響。 2020 年 3 月，美國總統宣布進入全國衛生緊急狀態，導致全國范圍內的非必要活動暫停。包括美國外科醫師學會 (ACS) 在內的主要外科學會在 3 月中旬宣布，盡量減少、推遲或取消擇期手術，並發布了按外科專業進行擇期手術分診的指南。醫療保險和醫療補助服務中心 (CMS) 和美國外科醫生也發表聲明，建議推遲不必要的手術。 2022 年 2 月，發表在《外科前沿》上的一篇論文發現，在大流行期間推遲擇期手術導致外科診所的手術減少。手術量的下降表明大流行後外科診所和醫院的工作量嚴重增加。

此外，大流行的擔憂正在推遲對常見腫瘤，尤其是乳腺癌的診斷，從而導致腫瘤進一步進展和疾病進展。此外，在第一波大流行期間，乳腺癌手術數量，尤其是首次手術數量減少了約 50-60%。隨著我們從大流行中恢復過來，越來越多的醫院定期為患者提供足夠的護理，甚至為患者進行手術，從而推動了全球術後疼痛市場。

您可以在全球術後疼痛治療市場報告中訪問大約 70 多個市場數據表、65 多個圖表和 250 多個頁面（大約）。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按藥物類型：市場細分
  • 按管理途徑：市場細分
  • 按疼痛類型：市場細分
  • 按分銷渠道：市場細分
  • 按地區：市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 手術次數增加
      • 新藥上市數量增加
    • 限制
    • 與術後止痛藥相關的副作用
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類型

  • 阿片類藥物
  • 非甾體抗炎藥
  • 糖皮質激素
  • 局部麻醉劑
  • 三環類抗抑鬱藥
  • 抗癲癇藥
  • 其他

第 8 章給藥途徑

  • 口語
  • 靜脈給藥
  • 肌肉注射
  • 其他

第 9 章按疼痛類型

  • 神經性疼痛
  • 傷害性疼痛

第 10 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 電子商務
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 13 章公司簡介

  • Mallinckrodt 製藥公司
    • 公司概況
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • Trevena Inc.
  • Heron Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • Camarus
  • Bayer AG
  • Pacira BioSciences Inc.
  • Pfizer Inc.
  • Novartis AG
  • Hyloris Pharmaceuticals SA
  • Eli Lilly & Company

第 14 章全球術後止痛藥市場-DataM

簡介目錄
Product Code: DMPH5858

Market Overview

Post-Operative Pain Therapeutics Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Postsurgical or postoperative pain is long-lasting after surgery; it is nearly 3 to 6 months. The pain varies from patient to patient as well as quality and location from the pain experienced before the surgery, and it is usually related to iatrogenic neuropathic pain caused by surgical injury to a crucial peripheral nerve. While most all surgeries can lead to postoperative pain, some surgeries have a high risk of causing nerve damage, such as breast and thoracic surgery, leg amputation, inguinal hernia repair, and coronary artery bypass surgery. To reduce this pain, various medications are used, such as NSAIDs.

Market Dynamics

The post-operative pain therapeutics market growth is driven by the rise in the number of surgeries, launching of new drugs in the market and research and development activities, rising geriatric population in developing countries, growing prevalence of acute diseases, and increasing patient awareness related to surgeries and operations.

The rising number of surgeries is expected to drive the market growth

The rising number of different surgeries, such as cancer and eye, is expected to boost the market over the forecast period. As per the American Society of Plastic Surgeons 2020 data report, nearly 15.6 million cosmetic procedures were performed in 2020, of which 2.3 million were cosmetic surgical procedures and 13.2 million cosmetic minimally-invasive procedures. Furthermore, females have a higher number of cosmetic surgeries than males, with females performing approximately 92% of all cosmetic procedures and males performing approximately 8% of all cosmetic procedures in 2020. Furthermore, among the children who are in the 13-19 age group, only 2% of the total contributed to the surgeries. Some of the most common procedures for teens include eyelid surgery, nose reshaping, ear surgery, laser hair removal, and laser skin resurfacing. The healthcare professional recommended the NSAID drugs to reduce the pain of this after cosmetic surgery.

Moreover, according to the article published in the South African Journal of Physiology, osteoarthritis has an occurrence and progression rate of 22% at 40 years of age. At the more advanced stage of disease progression and when limited management fails to provide the individual with effective pain relief, then joint replacement surgery is recommended by the health care professional. The increase in surgeries simultaneously increases the demand for post-operative therapeutics worldwide.

The side effects of post-operative pain therapeutics will hamper the growth of the market

However, all drugs have side effects, for instance, all opioids have their side effects which is limiting their use. The major side effect related to the use of opioids is respiratory depression. The rising cases of a drug overdose and side effects associated with postoperative pain drugs are limits to the overall market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global post-operative pain therapeutics market. In March 2020, the United States president announced a national health emergency that resulted in a shutdown of all less necessary activities throughout the country. The American College of Surgeons (ACS) and other major surgical specialty societies declared that they would be minimizing, postponing, or canceling elective surgical procedures in mid-March and published guidelines for triage of elective surgical procedures by surgical specialty. The Centers for Medicare & Medicaid Services (CMS) and the US Surgeon General also published statements and gave suggestions for the postponement of unnecessary surgical procedures. In addition, in February 2022, as per the article published in Frontiers in Surgery the number of operations in surgical clinics was reduced because of the postponement of selective operations during the pandemic period. The drop in the number of surgeries indicates a serious rise in the workload on surgical clinics and hospitals in the post-pandemic period.

Furthermore, due to pandemic concerns, delays in diagnosis, especially in tumors of typical interest such as breast cancer, result in further advanced-stage tumors and disease progression. Moreover, the number of surgeries for breast cancer, especially upfront surgeries, dropped by around 50-60% in the first wave of the pandemic period. As the situation is recovering from the pandemic, more hospitals are regularly giving the proper treatment and they are performing surgeries on the patients, which is boosting the postoperative pain market worldwide.

Segment Analysis

The NSAIDs segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The NSAIDs segment is expected to boost the market over the period of the forecast. NSAIDs are a broad-ranging class of drugs with multiple characteristics such as cyclo-oxygenase (COX)-1 or COX-2 selectivity, targeted action, and analgesic potency. In March 2022, as per the article published in Pharmacological Management of Postoperative Pain, the clinical guidelines to manage postoperative pain were issued by the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, outlined a strong suggestion based on high-quality evidence that physicians or clinicians provide adult and paediatric patients with paracetamol or acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDs) as part of a multimodal analgesic regimen to handle the postoperative pain unless there are any specific contraindications. NSAIDs can have potent central effects similar to those of opioids. In addition, the quick onset of analgesic activity is a key prescribing consideration for treating acute postoperative pain. For instance, the study analysing and validating the rate of onset of a variety of NSAIDs in dental pain found that dexketoprofen 25 mg was so much faster (30 minutes) than diclofenac 50 mg (60 minutes), tramadol 100 mg (120 minutes), and piroxicam 20 mg (120 minutes). Because of its rapid onset of action, there is an increasing demand for NSAIDs in the market to treat postoperative pain.

Geographical Analysis

North America region holds the largest market share of the global post-operative pain therapeutics market

North America dominates the market for post-operative pain therapeutics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to increasing number of surgeries, advanced healthcare systems, easily availability of therapeutics for treatment. The launching new drugs development, research activity and approval of various drugs drive the market in the North American region. For instance, in March 2022, Virpax Pharmaceuticals, Inc. is completed all FDA-required pre-clinical studies for Epoladerm Virpax's investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (OA) of the knee. The key Investigational New Drug Application (IND) allows studies to be completed, on irritation, dermal toxicity phototoxicity and pharmacokinetic characteristics.

Furthermore, in June 2022, Heron Therapeutics, Inc. announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution as the foundation of a perioperative non-opioid multimodal analgesic (MMA) regimen in patients undergoing total knee arthroplasty (TKA). The ZYNRELEF is approved by the U.S. Food and Drug Administration (FDA) for use in adults for soft tissue or peri-articular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Competitive Landscape

The Post-operative Pain Therapeutics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Mallinckrodt Pharmaceuticals, Trevena Inc., Heron Therapeutics, Teva Pharmaceutical Industries Ltd., Camarus, Bayer AG, Pacira BioSciences Inc., Pfizer Inc., Novartis AG, Hyloris Pharmaceuticals SA, and Eli Lilly & Company among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the post-operative pain therapeutics market globally.

For instance,

  • In November 2021, Antibe Therapeutics Inc. is pleased to provide additional detail on otenaproxesul's development plan for acute pain indications. Further, this drugs can used for post-operative pain, as a safe non-opioid analgesic.

Hyloris Pharmaceuticals SA

Overview:

Hyloris is a biopharma company involved in innovating, reinventing, and optimizing existing medications to direct important healthcare necessities and deliver related improvements for patients, healthcare professionals and payors. Hyloris has a patented portfolio of 13 repurposed and reformulated modernized medicines that have the potential to provide remarkable advantages over other alternatives.

Treatment type Portfolio:

Maxigesic IV: Maxigesic IV is a novel, patented; non-opioid used for treatment of post-operative pain and is a distinctive combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion. It is currently licensed in more than 100 countries across the world, and registered in 24 countries. It is now available in 5 countries including Australia, New Zealand, The United Arab Emirates, Germany, and Austria.

The global post-operative pain therapeutics market report would provide access to approximately 70+ market data tables, 65+ figures, and in the range of 250+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market snippet By Route of Administration
  • 3.3. Market snippet By Type of Pain
  • 3.4. Market snippet By Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising Number of Surgeries
      • 4.1.1.2. The increasing launching of new drugs
    • 4.1.2. Restraints:
    • 4.1.3. The side effects related to post-operative pain therapeutics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Opioids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. NSAIDs
  • 7.4. Glucocorticoids
  • 7.5. Local Anesthetics
  • 7.6. Tricyclic Antidepressants
  • 7.7. Antiepileptic drugs
  • 7.8. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Intravenous
  • 8.4. Intramuscular
  • 8.5. Others

9. By Type of Pain

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain Market Attractiveness Index, By Type of Pain
  • 9.2. Neuropathic Pain*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nociceptive Pain

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. E-commerce
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. Mallinckrodt Pharmaceuticals*
    • 13.1.1. Company Overview
    • 13.1.2. Treatment type Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Trevena Inc.
  • 13.3. Heron Therapeutics
  • 13.4. Teva Pharmaceutical Industries Ltd.
  • 13.5. Camarus
  • 13.6. Bayer AG
  • 13.7. Pacira BioSciences Inc.
  • 13.8. Pfizer Inc.
  • 13.9. Novartis AG
  • 13.10. Hyloris Pharmaceuticals SA
  • 13.11. Eli Lilly & Company

LIST NOT EXHAUSTIVE

14. Global Post-operative Pain Therapeutics Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us